ArticleJournal of cancer research and clinical oncology2025
Global research landscape of retinoblastoma biomarkers: a multidisciplinary bibliometric analysis based on multiple databases (2005-2025).
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveResearch exploring biomarkers for retinoblastoma (RB) diagnosis exists; however, their specific impact on RB has not been thoroughly investigated through systematic quantitative analysis. This study aims to analyze the research landscape and hotspots of RB biomarkers from 2005 to 2025, providing a theoretical reference for future investigations.
methodsWe retrieved publications from the Web of Science and Scopus databases published between 2005 and 2025, followed by analysis using R software, VOSviewer, and CiteSpace tools.
resultsFrom 2005 to 2025, annual publication output exhibited a steady upward trajectory, with notably accelerated growth observed between 2013 and 2021, followed by a moderated pace from 2021 to 2024. China led in publication volume, followed by the United States, India, and Italy. While China dominated in quantitative output, the United States established a broader network of international collaborations. Cancers emerged as the journal with the highest publication count, whereas Cancer Research ranked first in citation frequency. Current research hotspots primarily include: liquid biopsy and circulating tumor biomarkers; molecular subtyping and tumor heterogeneity; targeted therapies and drug resistance mechanisms; tumor microenvironment and immune evasion; and artificial intelligence with multimodal data integration. Investigations into RB biomarkers focus on: (1) dynamically reflecting tumor burden (short half-life properties); (2) regulating oncogene transcription/translation (targeting E2F3, PI3K, and m6A); (3) driving epithelial-mesenchymal transition (EMT) and cellular proliferation; (4) mediating immune evasion; and (5) deep learning-based identification of tumor heterogeneity. The exploration of biomarkers to optimize individualized retinoblastoma treatment has emerged as a notable research trend.
conclusionAs an emerging tool for achieving personalized therapeutic optimization, biomarkers have garnered significant attention from global scholars and are poised to become a major focus in future research on the management of RB. This study systematically reviewed and analyzed the current research landscape and key issues surrounding RB biomarkers, aiming to provide valuable references and insights for subsequent research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.